What is Mabt?
Founded in 2011, Mid-Atlantic BioTherapeutics (Mabt) operates at the intersection of biotechnology and artificial intelligence to address critical gaps in modern medicine. The company focuses on developing innovative therapies for debilitating neurological conditions, such as Alzheimer's, Parkinson's, and ALS, while simultaneously tackling infectious diseases. A key component of its current market strategy involves the recent acquisition of XPose Therapeutics, a move designed to bolster its oncology pipeline and enhance its capabilities in treating difficult-to-manage cancers.
Mabt distinguishes itself through a rigorous scientific methodology that integrates AI-driven drug discovery with traditional therapeutic development. This dual-pronged approach allows the firm to identify and validate potential treatments with greater precision, ultimately aiming to improve patient outcomes in areas where current medical options remain limited. The company's commitment to compassionate innovation remains the cornerstone of its operational philosophy.
How much funding has Mabt raised?
Mabt has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2025): $50M with participation from Legend Innovators
Key Investors in Mabt
Legend Innovators
Legend Innovators is a business advisory firm based in Bhubaneswar, Odisha, that provides virtual CFO services, startup mentoring, and comprehensive fund-raising support to foster sustainable growth.
What's next for Mabt?
Looking ahead, the strategic deployment of this recent investment will likely focus on the integration of the XPose Therapeutics oncology assets and the advancement of its core neurological research programs. As the company transitions into this next phase of growth, stakeholders can expect an increased emphasis on clinical trial progression and the scaling of its AI-enabled research infrastructure. The firm is poised to leverage its strengthened balance sheet to navigate the complexities of the biotech landscape, focusing on long-term value creation through scientific breakthroughs and potential future partnerships. By maintaining its focus on unmet medical needs, Mabt is strategically positioned to influence the future of therapeutic intervention.
See full Mabt company page
